33 results on '"Mitlak, B."'
Search Results
2. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial
3. PMS79 PHASE 1B EVALUATION OF PATIENT EXPERIENCE WITH ABALOPARATIDE SOLID MICROSTRUCTURED TRANSDERMAL SYSTEM IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY
4. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
5. Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed by 24 Months of Alendronate
6. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture
7. Tools in the Assessment of Sarcopenia
8. Treatment of osteoporosis in men
9. Management of Glucocorticoid-Induced Osteoporosis
10. Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper
11. Frailty and sarcopenia: definitions and outcome parameters
12. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
13. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies
14. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
15. Effects of Arzoxifene on Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Mass.
16. Abstract: 1057 RALOXIFENE AND STROKE RISK BASED ON THE FRAMINGHAM STROKE RISK SCORE
17. Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting
18. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
19. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
20. Adherence to treatment of osteoporosis: a need for study
21. Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
22. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
23. Parathyroid hormone as a therapeutic agent
24. Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis
25. Geographic Differences in Bone Turnover: Data from a Multinational Study in Healthy Postmenopausal Women
26. S-9. Raloxifene Reduces the Risk of Incident Vertebral Fractures
27. S-4.
28. F090 Baseline characteristics do not affect the response to raloxifene hydrochloride in Japanese women with osteoporosis
29. A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia.
30. Diagnosis and Treatment of Osteoporosis
31. Intermittent bovine parathyroid hormone administration increases spinal bone density and 1,25 dihydroxyvitamin D in young and senile rats
32. Parathyroid Hormone-Related Peptide Mediates Hypercalcemia in an Islet Cell Tumor of the Pancreas
33. Parathyroid Function in Normocalcemic Renal Transplant Recipients: Evaluation by Calcium Infusion*
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.